Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 39

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

A novel pathway of levodopa metabolism by commensal Bifidobacteria

Cirstea, M. S., Creus-Cuadros, A., Lo, C., Yu, A. C., Serapio-Palacios, A., Neilson, S., Appel-Cresswell, S., Finlay, B. B.·2023·Scientific Reports
DOI 10.1038/s41598-023-45953-z
Open this paper in CoChat — free account

Abstract

The gold-standard treatment for Parkinson’s disease is levodopa (L-DOPA), which is taken orally and absorbed intestinally. L-DOPA must reach the brain intact to exert its clinical effect; peripheral metabolism by host and microbial enzymes is a clinical management issue. The gut microbiota is altered in PD, with one consistent and unexplained observation being an increase in Bifidobacterium abundance among patients. Recently, certain Bifidobacterium species were shown to have the ability to metabolize L-tyrosine, an L-DOPA structural analog. Using both clinical cohort data and in vitro experimentation, we investigated the potential for commensal Bifidobacteria to metabolize this drug. In PD patients, Bifidobacterium abundance was positively correlated with L-DOPA dose and negatively with serum tyrosine concentration. In vitro experiments revealed that certain species, including B. bifidum, B. breve, and B. longum, were able to metabolize this drug via deamination followed by reduction to the compound 3,4-dihydroxyphenyl lactic acid (DHPLA) using existing tyrosine-metabolising genes. DHPLA appears to be a waste product generated during regeneration of NAD +. This metabolism occurs at low levels in rich medium, but is significantly upregulated in nutrient-limited minimal medium. Discovery of this novel metabolism of L-DOPA to DHPLA by a common commensal may help inform medication management in PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-023-45953-z

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 38

  1. Contin, M. & Martinelli, P. Pharmacokinetics of levodopa. J. Neurol. 257, 253–261 (2010). · DOI
  2. Kalia, L. V. & Lang, A. E. Parkinson’s disease. Lancet 386, 896–912 (2015). · DOI · Paper page
  3. Tambasco, N., Romoli, M. & Calabresi, P. Levodopa in Parkinson’s disease: Current status and future developments. Curr. Neuropharmacol. 16, 1239 (2018). · DOI · Paper page
  4. Cenci, M. A. Presynaptic mechanisms of l-DOPA-induced dyskinesia: The findings, the debate, and the therapeutic implications. Front. Neurol. 5, 1–15 (2014). · DOI
  5. Pfeiffer, R. F., Isaacson, S. H. & Pahwa, R. Clinical implications of gastric complications on levodopa treatment in Parkinson’s disease. Parkinsonism Relat. Disord. 76, 63–71 (2020). · DOI · Paper page
  6. Laursen, M. F. et al. Bifidobacterium species associated with breastfeeding produce aromatic lactic acids in the infant gut. Nat. Microbiol. 6, 1367–1382 (2021). · DOI
  7. Toh, T. S. et al. Gut microbiome in Parkinson’s disease: New insights from meta-analysis. Park. Relat. Disord. 94, 1–9 (2022). · DOI
  8. Boertien, J. M., Pereira, P. A. B., Aho, V. T. E. & Scheperjans, F. Increasing comparability and utility of gut microbiome studies in Parkinson’s disease: A systematic review. J. Parkinson’s Dis. 9, S297–S312 (2019). · DOI
  9. Radisavljevic, N., Cirstea, M. & Brett Finlay, B. Bottoms up: The role of gut microbiota in brain health. Environ. Microbiol. 21, 3197–3211 (2019). · DOI
  10. Cirstea, M. S. et al. Microbiota composition and metabolism are associated with gut function in Parkinson’s disease. Mov. Disord. 35, 1208–1217 (2020). · DOI · Paper page
  11. Bover-Cid, S. & Holzapfel, W. H. Improved screening procedure for biogenic amine production by lactic acid bacteria. Int. J. Food Microbiol. 53, 33–41 (1999). · DOI
  12. Gummalla, S. & Broadbent, J. Tyrosine and phenylalanine catabolism by Lactobacillus cheese flavor adjuncts. J. Dairy Sci. 84, 1011–1019 (2001). · DOI
  13. Nakal, R. & Takagi, A. Establishment of a defined minimal medium and isolation of auxotrophic mutants for bifidobacterium bifidum ES 5. J. Gen. Appl. Microbiol. 29, 103–114 (1983). · DOI
  14. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014). · DOI · Paper page
  15. Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov. Disord. 22, 41–47 (2007). · DOI
  16. Aradi, S. D. & Hauser, R. A. Medical management and prevention of motor complications in Parkinson’s Disease. Neurotherapeutics 17, 1339–1365 (2020). · DOI
  17. Rivest, J., Barclay, C. & Suchowersky, O. COMT inhibitors in Parkinson’s disease. Can. J. Neurol. Sci. 26, S34-38 (1999). · DOI
  18. Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord. 25, 2649–2653 (2010). · DOI
  19. Wishart, D. S. et al. HMDB: The human metabolome database. Nucleic Acids Res. 35, 521–526 (2007). · DOI · Paper page
  20. Lavermicocca, P. et al. Purification and characterization of novel antifungal compounds from the sourdough lactobacillus plantarum strain 21B. Appl. Environ. Microbiol. 66, 4084 (2000). · DOI · Paper page
  21. Suzuki, Y. et al. Identification of antioxidants produced by Lactobacillus plantarum. Biosci. Biotechnol. Biochem. 77, 1299–1302 (2013). · DOI
  22. Yan, Z. et al. Alterations of gut microbiota and metabolome with Parkinson’s disease. Microb. Pathog. 160, 105187 (2021). · DOI
  23. Heilbronn, J., Wilson, J. & Berger, B. J. Tyrosine aminotransferase catalyzes the final step of methionine recycling in Klebsiella pneumoniae. J. Bacteriol. 181, 1739–1747 (1999). · DOI
  24. Paris, C. G. & Magasanik, B. Purification and properties of aromatic amino acid aminotransferase from Klebsiella aerogenes. J. Bacteriol. 145, 266–271 (1981). · DOI
  25. Kuramitsu, S., Inoue, K., Ogawa, T., Ogawa, H. & Kagamiyama, H. Aromatic amino acid aminotransferase of Escherichia coli: Nucleotide sequence of the tyrB gene. Biochem. Biophys. Res. Commun. 133, 134–139 (1985). · DOI
  26. Brown, S. A. & Whiteley, M. Characterization of the L-lactate dehydrogenase from Aggregatibacter actinomycetemcomitans. PLoS One 4, e7864 (2009). · DOI
  27. Yuan, Z. et al. Relationship between L-lactate dehydrogenase and multidrug resistance in Staphylococcus xylosus. Arch. Microbiol. https://doi.org/10.1007/s00203-021-02625-8 (2021). · DOI
  28. van Kessel, S. P. et al. Gut bacterial deamination of residual levodopa medication for Parkinson’s disease. BMC Biol. https://doi.org/10.1186/s12915-020-00876-3 (2020). · DOI · Paper page
  29. Rivière, A., Selak, M., Lantin, D., Leroy, F. & De Vuyst, L. Bifidobacteria and butyrate-producing colon bacteria: Importance and strategies for their stimulation in the human gut. Front. Microbiol. 7, 979 (2016). · DOI
  30. Unger, M. M. et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat. Disord. 32, 66–72 (2016). · DOI · Paper page
  31. Weis, S. et al. Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota. npj Park. Dis. https://doi.org/10.1038/s41531-019-0100-x (2019). · DOI · Paper page
  32. Sasahara, K. et al. Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs. J. Pharm. Sci. 70, 730–733 (1981). · DOI
  33. Bianchine, J. R., Messiha, F. S. & Hsu, T. H. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa. Clin. Pharmacol. Ther. 13, 584–594 (1972). · DOI
  34. Bedarf, J. R. et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients. Genome Med. https://doi.org/10.1186/s13073-017-0428-y (2017). · DOI · Paper page
  35. Heintz-Buschart, A. et al. The nasal and gut microbiome in Parkinson’s disease and idiopathic rapid eye movement sleep behavior disorder. Mov. Disord. 33, 88–98 (2018). · DOI · Paper page
  36. Bercik, P. et al. Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology 139, 2102–2112 (2010). · DOI · Paper page
  37. Bercik, P. et al. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut–brain communication. Neurogastroenterol. Motil. 23, 1132–1139 (2011). · DOI · Paper page
  38. Ait-Belgnaoui, A. et al. Probiotic gut effect prevents the chronic psychological stress-induced brain activity abnormality in mice. Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc. 26, 510–520 (2014). · DOI · Paper page

Metadata

Authors
Cirstea, M. S., Creus-Cuadros, A., Lo, C., Yu, A. C., Serapio-Palacios, A., Neilson, S., Appel-Cresswell, S., & Finlay, B. B.
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2023-11-06
Volume
13
Issue
1
ISSN
2045-2322
DOI
10.1038/s41598-023-45953-z
Cited by
39
References
5
Language
en
Licence
Funders
  • Canadian Institutes of Health Research (FDN-159935)
  • Pacific Parkinson's Research Institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.